Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Robert Marsh

Showing results (41-50 of 46) with videos related to

Pageof 5
Sort By:
You have reached the last page of results.This site can display upto 46 results.
Nature|August 16, 2018
Biologists ignore ocean weather at their perilAmanda E Bates, Brian Helmuth, Michael T Burrows, et al.
Annals of Surgical Oncology|February 26, 2013
Borderline resectable pancreatic cancer: need for standardization and methods for optimal clinical trial designMatthew H G Katz, Robert Marsh, Joseph M Herman, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 28, 2019
Clinical Assessment of 5-Fluorouracil/Leucovorin, Nab-Paclitaxel, and Irinotecan (FOLFIRABRAX) in Untreated Patients with Gastrointestinal Cancer Using <i>UGT1A1</i> Genotype-Guided DosingSmita S Joshi, Daniel V T Catenacci, Theodore G Karrison, et al.
BMC Cancer|July 29, 2017
Alliance for clinical trials in oncology (ALLIANCE) trial A021501: preoperative extended chemotherapy vs. chemotherapy plus hypofractionated radiation therapy for borderline resectable adenocarcinoma of the head of the pancreasMatthew H G Katz, Fang-Shu Ou, Joseph M Herman, et al.
JAMA Oncology|July 14, 2022
Efficacy of Preoperative mFOLFIRINOX vs mFOLFIRINOX Plus Hypofractionated Radiotherapy for Borderline Resectable Adenocarcinoma of the Pancreas: The A021501 Phase 2 Randomized Clinical TrialMatthew H G Katz, Qian Shi, Jeff Meyers, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 4, 2015
Randomized Phase Ib/II Study of Gemcitabine Plus Placebo or Vismodegib, a Hedgehog Pathway Inhibitor, in Patients With Metastatic Pancreatic CancerDaniel V T Catenacci, Melissa R Junttila, Theodore Karrison, et al.
Pageof 5

Showing results (41-50 of 46) with videos related to

Sort By:
Pageof 5
You have reached the last page of results.This site can display upto 46 results.
Nature|August 16, 2018
Biologists ignore ocean weather at their perilAmanda E Bates, Brian Helmuth, Michael T Burrows, et al.
Annals of Surgical Oncology|February 26, 2013
Borderline resectable pancreatic cancer: need for standardization and methods for optimal clinical trial designMatthew H G Katz, Robert Marsh, Joseph M Herman, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 28, 2019
Clinical Assessment of 5-Fluorouracil/Leucovorin, Nab-Paclitaxel, and Irinotecan (FOLFIRABRAX) in Untreated Patients with Gastrointestinal Cancer Using <i>UGT1A1</i> Genotype-Guided DosingSmita S Joshi, Daniel V T Catenacci, Theodore G Karrison, et al.
BMC Cancer|July 29, 2017
Alliance for clinical trials in oncology (ALLIANCE) trial A021501: preoperative extended chemotherapy vs. chemotherapy plus hypofractionated radiation therapy for borderline resectable adenocarcinoma of the head of the pancreasMatthew H G Katz, Fang-Shu Ou, Joseph M Herman, et al.
JAMA Oncology|July 14, 2022
Efficacy of Preoperative mFOLFIRINOX vs mFOLFIRINOX Plus Hypofractionated Radiotherapy for Borderline Resectable Adenocarcinoma of the Pancreas: The A021501 Phase 2 Randomized Clinical TrialMatthew H G Katz, Qian Shi, Jeff Meyers, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 4, 2015
Randomized Phase Ib/II Study of Gemcitabine Plus Placebo or Vismodegib, a Hedgehog Pathway Inhibitor, in Patients With Metastatic Pancreatic CancerDaniel V T Catenacci, Melissa R Junttila, Theodore Karrison, et al.
Pageof 5